Alicia Jenkins

NHMRC Clinical trials Centre, University of Sydney

Dr Jenkins is an Endocrinologist with particular interests in the prediction and prevention of the vascular complications of diabetes, the mechanisms of vascular tissue damage and protection, and the use of clinical, biochemical and molecular biomarkers and the use of technology in healthcare, including insulin pumps, glucose sensors and telehealth. She holds a NHMRC Practitioner Fellowship (2017-2021) related to diabetes. The team has a wide array of instrumentation and experience with over 400 biochemical and molecular biomarkers related to glycaemia, adiposity, oxidative stress, inflammation and AGEs. The group usually publishes 15 or more peer-reviewed manuscripts per year. During her career she has received >$72 million research funding, including funds from NHMRC, DART, NHF and JDRF Australia; the NIH, ADA and JDRF International, and industry (Medtronic, Sanofi-Aventis, Eli Lilly, Novo and Firefly). Alicia has active collaborations with researchers in Australia and overseas (USA, Canada, UK / EU, India, Hong Kong, China, Qatar), including with the investigators of the following cohort studies: FIELD, DCCT/EDIC, VA Diabetes Trial, REMOVAL, FAMAS, T4DM, PROGRESS, pre-eclampsia in T1DM, ALGOS, INITIATION, the Australian Closed Loop Insulin Pump Studies and the GP-Osmotic Study. She has diabetes related collaborations, including investigator initiated studies, with Medtronic, NMR (Liposcience Inc), Atherotech, Abbott and Sanofi-Aventis and pharma led studies including with Medtronic, Novo and Eli Lilly. For 2015-2017 Alicia is on the Executive Council of the International Diabetes Federation (IDF) Western Pacific. In 2012 Alicia completed an 8-year term on the Australian Diabetes Society (ADS) Council, including four years on the Executive as Treasurer. She remains the ADS representative for the Disaster Response Committee and on the editorial board of Diabetes Management Journal. She was a member of the NHMRC Type 1 diabetes guidelines and chaired the recently published Guidelines regarding medical consultations with adults with Type 1 diabetes. She is on the Steering Committee of Australia’s JDRF Clinical Research Network and leads the JDRF Australia research node at the NHMRC Clinical Trials Centre. She is President of the diabetes aid charity Insulin For Life Global and on the Boards of IFL Global, IFL Australia and IFL USA. She is on the advisory board of the IDF Life For a Child Program which supports over 18,000 youth with diabetes in 48 disadvantaged countries. She is on the IDF Insulin Task Force.